Business
Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors
Douglas Fisher, MD will assume the role of interim Chairman of the BoardNEW HAVEN, CT / ACCESSWIRE / December 4, 2019 / Specialty diagnostics company
About this update from Precipio, Inc.
[{"type":"text","content":"Douglas Fisher, MD will assume the role of interim Chairman of the BoardNEW HAVEN, CT / ACCESSWIRE / December 4, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced the resignation of Samuel Riccitelli from the board of directors, and his replacement by Richard Sandberg. The transition was ratified at the company's recent board of directors meeting and is effective as of December 1st, 2019.Mr. Riccitelli decided to resign so that he can focus on his recently accepted position as the Chief Executive Officer of Pathnostics, a diagnostics company focused on improving antibiotic stewardship through better diagnosis and treatment selection for patients suffering from urinary tract infections.\"Over the years I have watched Precipio overcome tremendous hurdles on its quest to address the devastating problem of misdiagnosis with their effective suite of products and services which are poised to deliver superior outcomes,'' said Mr. Riccitelli. \"I am confident that the current board and management team will continue to deliver results that have an outsized impact on the healthcare industry\".\"It has been a pleasure to call Sam my colleague, mentor and friend,'' said Ilan Danieli. \"Although no longer formally on our board, I am confident Sam will remain all of those. Pathnostics is lucky to have him, and I wish him the best of success\".Richard SandbergJoining the board is Richard Sandberg, a seasoned diagnostics executive with a substantial track record in the field. Mr. Sandberg brings a wealth of executive experience to the corporate development and strategic direction of Precipio, having founded Dianon Systems, Inc., a leading anatomic pathology laboratory based in Stratford, CT and having served at various times as Chairman, Chief Executive Officer and Chief Financial Officer. Dianon was acquired by Labcorp for $650M in 2002. Mr. Sandberg has since held a number of positions in the diagnostics products and services industry including Chairman of Oxford Immunotec, Ltd, Chairman of Concile GmbH, Chairman of SuperNova Diagnostics, Inc., Chairman of Lifecodes Corporation, Director of Poplar Healthcare LLC, Director of Cylex, Inc., and Chief Financial Officer and Director of Matritech, Inc. Mr. Sandberg also serves as Chief Executive Officer of Resolys Bio, Inc, a pharmaceutical company which is developing a p...